文献速递泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤

局限性前列腺癌大分割放疗后迟发性直肠出血的患者相关危险因素:单中心回顾性研究

Patient-related risk factors for late rectal bleeding after hypofractionated radiotherapy for localized prostate cancer: a single-center retrospective study.
PubMed 文献 · Radiat Oncol · 2022-02-09

该单中心回顾性研究纳入231例接受大分割放疗(70或67.2 Gy/28次)的局限或局部晚期前列腺癌患者,分析迟发性直肠出血的患者相关危险因素。中位随访23个月,≥1级、≥2级、≥3级迟发性直肠出血粗率分别为23.8%、16.9%、9.5%。多因素分析显示肝硬化和抗凝药物使用预测≥3级直肠出血风险增加(HR分别为14.37和2.93)。

要点

  • 肝硬化和抗凝药物使用是≥3级迟发性直肠出血的独立危险因素。
  • 抗凝组5年≥3级出血免于发生率显著低于非抗凝组(76.7% vs 88.0%,P=0.041)。
  • 抗凝患者直肠EQD2 V77 Gy<4.5%或EQD2 V8.2 Gy<71.0%时出血风险最小化。

核心结论

  • 本研究中,服用抗凝药物或患有肝硬化的患者在大分割放疗后发生严重迟发性直肠出血的风险显著高于其他患者。
  • 通过最小化抗凝患者的 hotspots 可降低出血风险。

研究设计与样本

  • 单中心回顾性研究,共评估231例接受大分割放疗(70或67.2 Gy/28次)的局限或局部晚期前列腺癌患者。
  • 所有患者接受调强放疗并每日图像引导。
  • 分析迟发性直肠出血与糖尿病、高血压、肝硬化、抗凝药物使用等危险因素的关系。

主要发现

  • 中位随访23个月,≥1级、≥2级、≥3级迟发性直肠出血粗率分别为23.8%、16.9%、9.5%。
  • 多因素分析显示肝硬化预测≥3级直肠出血风险增加(HR 14.37,95%CI 3.09-66.87,P=0.001)。
  • 多因素分析显示抗凝药物使用预测≥3级直肠出血风险增加(HR 2.93,95%CI 1.14-7.55,P=0.026)。
  • 倾向加权log-rank分析显示非抗凝组5年≥3级出血免于发生率显著优于抗凝组(88.0% vs 76.7%,P=0.041)。
  • ROC曲线分析显示抗凝组直肠EQD2 V77 Gy<4.5%或EQD2 V8.2 Gy<71.0%时直肠出血最小化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Several studies have reported patient-related risk factors for late rectal bleeding following conventionally fractionated radiotherapy for prostate cancer. We investigated patient-related risk factors for late rectal bleeding after hypofractionated radiotherapy. METHODS: A total of 231 patients with local or locally advanced prostate cancer treated with hypofractionated radiotherapy (70 or 67.2 Gy in 28 fractions) were evaluated retrospectively. All patients received intensity-modulated radiotherapy with daily image guidance. The relationships between late rectal bleeding and risk factors like diabetes, hypertension, cirrhosis, and anticoagulant use were analyzed. RESULTS: During a median follow-up of 23 months, the crude rates of grade ≥ 1, grade ≥ 2, and grade ≥ 3 late rectal bleeding were 23.8%, 16.9%, and 9.5%, respectively. Cirrhosis and anticoagulant use predicted an increased risk of grade ≥ 3 rectal bleeding in multivariable analyses (hazard ratio [HR] 14.37, 95% confidence interval [CI] 3.09-66.87, P = 0.001, and HR 2.93, 95% CI 1.14-7.55, P = 0.026, respectively). The non-anticoagulant group had a significantly superior 5-year freedom from grade ≥ 3 bleeding compared to the anticoagulant group in a propensity-weighted log-rank analysis (88.0% vs. 76.7%, P = 0.041). A receiver operating characteristic curve analysis revealed that rectal bleeding was minimized in the anticoagulant group if the equivalent dose at fractionation of 2 Gy (EQD2) V77 Gy of the rectum was < 4.5% or if the EQD2 V8.2 Gy was < 71.0%. CONCLUSIONS: Patients taking anticoagulants or those with cirrhosis had a significantly higher risk of severe late rectal bleeding than other patients after hypofractionated radiotherapy for prostate cancer in the present study. The bleeding risk could be lowered by minimizing hotspots in patients taking anticoagulants.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Kim TG, Park B, Song YG, et al. Patient-related risk factors for late rectal bleeding after hypofractionated radiotherapy for localized prostate cancer: a single-center retrospective study. Radiat Oncol. 2022. PMID: 35139869. doi:10.1186/s13014-022-01998-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。